Back
Zoetis Inc. (ZTS)
PharmaceuticalsZTS · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$75.10
−1.56%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$6.02
ROE
67.7%
Gross margin
71.8%
Debt/Equity
2.86x
Revenue growth
2.9%
Zoetis Inc. — company intelligence
Earnings surprises
Q1 2026$1.53 vs $1.63 est-6.2%
Q4 2025$1.48 vs $1.42 est+4.5%
Q3 2025$1.70 vs $1.64 est+3.8%
Q2 2025$1.76 vs $1.63 est+7.8%
Insider activity · 90 days
4 buys1 sellnet +11,893 shares
Stetter MarkBuy 318 · Jun 18, 2026
MCCALLISTER MICHAEL Bgift 1,209 · Jun 10, 2026
Stetter Markother 1,572 · May 21, 2026
Recent SEC filings
4 — Insider transaction reportJun 22, 2026
4 — Insider transaction reportJun 11, 2026
4 — Insider transaction reportMay 26, 2026
Latest news
Deadly Screwworm’s Leap Into the US Mystifies Health Experts — Yahoo · 5d ago
Zoetis: The 60% Decline Was Justified, But Shares Are Finally Buyable — SeekingAlpha · 5d ago
Zoetis Inc (NYSE:ZTS) Offers High-Quality Dividend Growth and Strong Profitability at a Discount — ChartMill · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Zoetis Inc.
Weekly undervalued picks (like ZTS)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.